908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
1. Repligen acquired 908 Devices' MASS desktop portfolio for $70 million. 2. This acquisition enhances Repligen's bioprocessing analytical technology offerings. 3. 908 Devices saw a 31% revenue increase, supporting market demand. 4. Desktop revenue growth indicates potential synergy with Repligen's existing portfolio. 5. MASS stock rose 71.7% following the acquisition announcement.